169 related articles for article (PubMed ID: 37126456)
1. Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers.
Quan B; Bailey MA; Mantyh J; Hsu DS; Fitzgerald MC
J Proteome Res; 2023 Jun; 22(6):1923-1935. PubMed ID: 37126456
[TBL] [Abstract][Full Text] [Related]
2. A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer.
Kendzia S; Franke S; Kröhler T; Golob-Schwarzl N; Schweiger C; Toeglhofer AM; Skofler C; Uranitsch S; El-Heliebi A; Fuchs J; Punschart A; Stiegler P; Keil M; Hoffmann J; Henderson D; Lehrach H; Yaspo ML; Reinhard C; Schäfer R; Keilholz U; Regenbrecht C; Schicho R; Fickert P; Lax SF; Erdmann F; Schulz MH; Kiemer AK; Haybaeck J; Kessler SM
Mol Cancer; 2023 May; 22(1):89. PubMed ID: 37248468
[TBL] [Abstract][Full Text] [Related]
3. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
4. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
5. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
[TBL] [Abstract][Full Text] [Related]
6. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
7. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
8. MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.
Zhou Y; He A; Zhang L; Yi G
Neoplasma; 2020 Mar; 67(2):296-303. PubMed ID: 31884801
[TBL] [Abstract][Full Text] [Related]
9. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
10. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity.
Di Y; Jing X; Hu K; Wen X; Ye L; Zhang X; Qin J; Ye J; Lin R; Wang Z; He W
Drug Resist Updat; 2023 Jan; 66():100909. PubMed ID: 36525936
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
[TBL] [Abstract][Full Text] [Related]
12. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
[TBL] [Abstract][Full Text] [Related]
13. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
Choi TG; Nguyen MN; Kim J; Jo YH; Jang M; Nguyen NNY; Yun HR; Choe W; Kang I; Ha J; Tang DG; Kim SS
J Pathol; 2018 Sep; 246(1):115-126. PubMed ID: 29876924
[TBL] [Abstract][Full Text] [Related]
14. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
Yang Y; Jiang H; Li W; Chen L; Zhu W; Xian Y; Han Z; Yin L; Liu Y; Wang Y; Pan K; Zhang K
Aging (Albany NY); 2020 Dec; 12(23):24424-24440. PubMed ID: 33291076
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer.
Huang CZ; Zhou Y; Tong QS; Duan QJ; Zhang Q; Du JZ; Yao XQ
Biomaterials; 2022 Nov; 290():121827. PubMed ID: 36228517
[TBL] [Abstract][Full Text] [Related]
16. Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.
Zhang B; Chan SH; Liu XQ; Shi YY; Dong ZX; Shao XR; Zheng LY; Mai ZY; Fang TL; Deng LZ; Zhou DS; Chen SN; Li M; Zhang XD
J Cell Mol Med; 2021 Sep; 25(18):8836-8849. PubMed ID: 34378321
[TBL] [Abstract][Full Text] [Related]
17. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer.
Misbah M; Kumar M; Lee KH; Shen SC
Biomed Res Int; 2022; 2022():3825760. PubMed ID: 36193307
[TBL] [Abstract][Full Text] [Related]
19. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
Xu Y; Zhu M
Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
[TBL] [Abstract][Full Text] [Related]
20. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]